Premium
Intracranial dissemination of a macroprolactinoma
Author(s) -
Assies J.,
Verhoeff N. P. L. G.,
Bosch D. A.,
Hofland L. J.
Publication year - 1993
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1993.tb00351.x
Subject(s) - bromocriptine , medicine , agonist , prolactin , dopamine agonist , ptosis , dopamine , positron emission tomography , endocrinology , in vivo , nuclear medicine , surgery , receptor , biology , microbiology and biotechnology , hormone
Summary A patient with a macroprolactinoma and extrasellar extension was treated by incomplete transfrontal surgery, external irradiation and additional bromocriptine (Br) treatment. After 4 years, partial bromocriptine resistance developed (a rare occurrence) together with the appearance of intracranial metastases. 123 l‐lodobenzamide was helpful In evaluating the dopamine D2 receptor status of the metastatic tumour both in vivo using single‐photon emission computed tomography (SPECT) and in vitro. Prolactin release by the cultured metastatic tumour cells was more potently inhibited by CV 205–502 than by bromocriptine. The patient, treated by surgery, irradiation and CV 205–502, developed a ptosis of the left eye and a transient psychiatric delusional state, the latter probably an effect of the dopamine agonist. As the right frontal metastasis was markedly positive on SPECT with 111 ln‐SMS, somatostatin treatment was added to the CV 205–502.